German prosecutors charged two former board members of Greensill Bank AG for their roles in the 2021 demise of the lender.The men are charged with bankruptcy crimes and false accounting, a spokesman for Bremen prosecutors said in an emailed statement. A member of the unit’s supervisory board was also indicted. The statement didn’t identify any of the accused. The probe in Germany is just one of a number of court claims and investigations sparked by the collapse of Greensill’s trade financing business. The f ...

Brian Lee from Goldman Sachs sets a price target of $26 for NASDAQ:FLNC, indicating a potential increase of about 40%.Caxton Associates LLP acquires 530,633 shares, showing strong institutional confidence in Fluence Energy's future performance.Despite a current decrease of -12.86% in stock price, significant increases in institutional ownership reflect optimism for FLNC's growth potential.Fluence Energy, Inc. (NASDAQ:FLNC) specializes in energy storage solutions, competing with giants like Tesla and Siemens ...

Edinburgh Worldwide Investment Trust, a Baillie Gifford-run technology-focused fund, is calling on shareholders to throw out a plan by Boaz Weinstein's activist investment fund Saba Capital to overhaul its board of directors.The EWIT board said on Wednesday it would "strongly urge" shareholders to reject a plan by the U.S. hedge fund — which holds a 30% stake in the trust — to remove the incumbent board and appoint three directors in their place.In an update on Wednesday, the trust's chair, Jonathan Simpson ...

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is listed on both SIX and NASDAQ under the ticker MOLN and was founded in 2004 [3] - The company has its headquarters in Zurich, Switzerland, and an office in Concord, Massachusetts, USA [3] - The primary focus of the company is oncology, with various programs in different stages of pre-clinical and clinical development [3] Group 2: Upcoming Events - The CEO, Patrick Amstutz, will present the latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025, from 10:30 AM to 11:10 AM PT [2] - A webcast of the presentation will be available on the Molecular Partners website under the Events tab [2] Group 3: Strategic Partnerships - Molecular Partners collaborates with leading pharmaceutical companies to leverage the advantages of DARPins and provide unique solutions to patients [3]

Core Insights - The iShares Russell 2000 Value ETF (IWN) has outperformed the iShares S&P Mid-Cap 400 Value ETF (IJJ) over the past year, but IJJ has shown stronger historical performance over longer periods [1][8][10] Comparison of ETFs - IWN targets small-cap value companies, while IJJ focuses on mid-cap value stocks, highlighting differences in cost, returns, risk, sector focus, and portfolio construction [2][10] - IWN has a higher one-year return of 8.1% compared to IJJ's 3.8%, but IJJ has a lower expense ratio of 0.18% versus IWN's 0.24% [3][10] - IWN has assets under management (AUM) of $11.8 billion, while IJJ has $8.0 billion [3] Performance Metrics - Over the last five years, IJJ has a max drawdown of 22.7%, while IWN's is 26.7% [4] - Growth of $1,000 over five years is $1,695 for IJJ and $1,549 for IWN [4] Holdings and Sector Focus - IWN tracks over 1,400 small-cap U.S. value stocks, with financial services making up 27% of its assets, followed by industrials at 13% and healthcare at 10% [5] - IJJ holds about 295 mid-cap value stocks, with financial services at 21%, industrials at 17%, and consumer cyclical at 11% [6] Historical Returns - Since 2000, IJJ has posted total returns of approximately 1,060%, while IWN's returns are around 777% [8] - Both ETFs have underperformed compared to the S&P 500 but offer different holdings compared to the broader index [9] Investment Considerations - Both ETFs provide diversification away from large-cap tech stocks, with IJJ being favored for its historical returns, lower expense ratio, and slightly higher dividend yield [10][11]

Snowflake Inc. (NYSE:SNOW) is one of the Top AI and Technology Stocks to Buy According to Hedge Funds. On December 3, the company released its financial results for Q3 2026, with revenue coming at $1.21 billion, reflecting 29% YoY growth amidst 29% YoY growth in product revenue to $1.16 billion. Snowflake (SNOW) Releases Financial Results for Q3 2026 Snowflake Inc. (NYSE:SNOW)’s product revenue rose $258.1 million and $726.6 million for 3 and 9 months ended October 31, 2025 on a YoY basis, respectively, ...

AppLovin Corporation (NASDAQ:APP) is one of the Top AI and Technology Stocks to Buy According to Hedge Funds. On December 11, Benchmark analyst Mike Hickey lifted the price target on the company’s stock to $775 from $700, while keeping a “Buy” rating. The firm believes that the company’s prospects have strengthened, thanks to the accelerating e-commerce traction and a clear roadmap to scale AXON Ads self-serve. Also, expansion of Gen AI creative capabilities and sustained margin durability are some of the ...

Salesforce, Inc. (NYSE:CRM) is one of the Top AI and Technology Stocks to Buy According to Hedge Funds. On December 9, Morgan Stanley reduced the price target on the company’s stock to $398 from $405 while keeping an “Overweight” rating, as reported by The Fly. This comes after the firm adjusted estimates and valuations among its software coverage following Salesforce, Inc. (NYSE:CRM)’s strong earnings report. Morgan Stanley Reduces PT on Salesforce (CRM) Stock Elsewhere, on December 3, Salesforce, Inc. ...

Oracle Corporation (NYSE:ORCL) is one of the Top AI and Technology Stocks to Buy According to Hedge Funds. On December 10, the company announced its Q2 2026 financial results, with total remaining performance obligations rising 438% YoY in USD to $523 billion. Notably, Oracle Corporation (NYSE:ORCL) highlighted that its RPO rose by $68 billion in Q2 2026, an increase of 15% sequentially. This was highlighted by new commitments from Meta, NVIDIA, and others. Oracle (ORCL) Announces Q2 2026 Financial Result ...

Apple Inc. (NASDAQ:AAPL) is one of the Top AI and Technology Stocks to Buy According to Hedge Funds. On December 8, Evercore ISI lifted the price target on the company’s stock to $325 from $300, while keeping an “Outperform” rating on the company’s stock. As per the analyst, Apple Inc. (NASDAQ:AAPL)’s upcoming Siri 2.0, powered by Gemini, is expected to act as a catalyst for potential upside in profits and valuation. The strategic launch has been planned for March 2026. Evercore ISI Raises PT on Apple (AA ...